Gender, n (%)
| | | | | | | | |
Male
|
60 (57)
|
739 (63)
|
60 (58)
|
234 (64)
|
84 (58)
|
888 (64)
|
36 (57)
|
85 (62)
|
Female
|
45 (43)
|
426 (37)
|
44 (42)
|
133 (36)
|
62 (42)
|
508 (36)
|
27 (43)
|
51 (38)
|
Median age, years (range)
|
62 (23–69)
|
61 (19–69)
|
76 (70–100)
|
73 (70–85)
|
65 (23–74)
|
63 (19–74)
|
78 (75–100)
|
77 (75–85)
|
ECOG performance status, n (%)
|
(n = 103)
|
(n = 1144)
|
(n = 101)
|
(n = 362)
|
(n = 142)
|
(n = 1372)
|
(n = 62)
|
(n = 134)
|
0
|
52 (50)
|
435 (38)
|
38 (38)
|
112 (31)
|
67 (47)
|
514 (37)
|
23 (37)
|
33 (25)
|
1
|
38 (37)
|
599 (52)
|
48 (48)
|
199 (55)
|
56 (39)
|
719 (52)
|
30 (48)
|
79 (59)
|
2
|
11 (11)
|
108 (9)
|
13 (13)
|
41 (11)
|
17 (12)
|
129 (9)
|
7 (11)
|
20 (15)
|
3
|
2 (2)
|
2 (<1)
|
2 (2)
|
9 (2)
|
2 (1)
|
9 (1)
|
2 (3)
|
2 (1)
|
4
|
0
|
0
|
0
|
1 (<1)
|
0
|
1 (0)
|
0
|
0
|
Metastatic site, n (%)
a
| | | | | | | | |
Liver
|
69 (66)
|
849 (73)
|
73 (70)
|
253 (69)
|
98 (67)
|
1014 (73)
|
44 (70)
|
88 (64)
|
Lung
|
29 (28)
|
323 (28)
|
31 (30)
|
100 (27)
|
42 (29)
|
385 (28)
|
18 (29)
|
38 (28)
|
Bone
|
1 (1)
|
45 (4)
|
2 (2)
|
8 (2)
|
2 (1)
|
50 (4)
|
1 (2)
|
3 (2)
|
Other
|
32 (30)
|
311 (27)
|
22 (21)
|
82 (22)
|
41 (28)
|
361 (25)
|
14 (22)
|
32 (23)
|
No. of metastatic sites, n (%)
|
(n = 100)
|
(n = 1105)
|
(n = 102)
|
(n = 335)
|
(n = 140)
|
(n = 1317)
|
(n = 62)
|
(n = 123)
|
1
|
73 (73)
|
732 (66)
|
78 (76)
|
238 (71)
|
104 (74)
|
883 (67)
|
47 (76)
|
87 (71)
|
>1
|
27 (27)
|
373 (34)
|
24 (24)
|
97 (29)
|
36 (26)
|
434 (33)
|
15 (24)
|
36 (29)
|
Local recurrence, %
|
44 (45)
|
526 (51)
|
40 (42)
|
176 (53)
|
58 (42)
|
638 (51)
|
26 (46)
|
64 (51)
|
Median CEA, ng/mL (range)
|
(n = 92)
|
(n = 926)
|
(n = 91)
|
(n = 302)
|
(n = 126)
|
(n = 1113)
|
(n = 57)
|
(n = 115)
|
19.8 (0.4–3312.7)
|
21.2 (0–14671)
|
13.7 (0.1–1175)
|
21.9 (0.7–25305)
|
17.2 (0.4–3312.7)
|
20.9 (0–25305)
|
22.7 (0.1–1175)
|
25.6 (0.7–6848)
|
Prior chemotherapy, n (%)
|
(n = 53)
|
(n = 670)
|
(n = 47)
|
(n = 190)
|
(n = 73)
|
(n = 786)
|
(n = 27)
|
(n = 74)
|
Adjuvant
|
35 (66)
|
453 (68)
|
33 (70)
|
127 (67)
|
47 (64)
|
534 (68)
|
21 (78)
|
46 (62)
|
Neoadjuvant
|
9 (17)
|
67 (10)
|
2 (4)
|
24 (13)
|
10 (14)
|
79 (10)
|
1 (4)
|
12 (16)
|